Company Quick10K Filing
Medovex
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 99 $41
10-Q 2019-11-14 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-04-10 Annual: 2018-12-31
10-Q 2018-11-14 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-11 Quarter: 2018-03-31
10-K 2018-03-30 Annual: 2017-12-31
10-Q 2017-11-20 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-31 Annual: 2016-12-31
10-Q 2016-11-17 Quarter: 2016-09-30
10-Q 2016-08-22 Quarter: 2016-06-30
10-Q 2016-05-16 Quarter: 2016-03-31
10-K 2016-04-14 Annual: 2015-12-31
10-Q 2015-11-13 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-14 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
8-K 2020-01-21 Regulation FD, Exhibits
8-K 2019-12-06 Officers, Exhibits
8-K 2019-11-21 Enter Agreement, Sale of Shares, Officers, Amend Bylaw, Regulation FD, Exhibits
8-K 2019-11-01 Enter Agreement, Exhibits
8-K 2019-10-02 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-07-31 Enter Agreement, Off-BS Arrangement, Officers, Regulation FD, Exhibits
8-K 2019-07-15 Amend Bylaw, Regulation FD, Exhibits
8-K 2019-06-26 Enter Agreement, Regulation FD, Exhibits
8-K 2019-06-17 Officers
8-K 2019-04-30 Officers
8-K 2019-04-05 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-03-15 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-02-15 Officers
8-K 2019-02-08 Enter Agreement, Off-BS Arrangement, Sale of Shares, Officers, Exhibits
8-K 2019-01-25 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-01-14 Enter Agreement, M&A, Off-BS Arrangement, Sale of Shares, Officers, Regulation FD, Exhibits
8-K 2018-12-21 Enter Agreement, Shareholder Rights, Exhibits
8-K 2018-10-18 Enter Agreement, Sale of Shares, Control, Officers, Amend Bylaw, Regulation FD, Exhibits
8-K 2018-10-15 Enter Agreement, Off-BS Arrangement, Sale of Shares, Officers, Regulation FD, Exhibits
8-K 2018-05-09 Enter Agreement, Sale of Shares, Amend Bylaw, Exhibits
8-K 2018-03-01 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-02-06 Enter Agreement, Officers, Exhibits

Medovex Financials

MDVX Metrics, Comps, Filings

Annual | Quarterly

Business

MedoveX was incorporated in Nevada on July 30, 2013 as SpineZ Corp. MedoveX is the parent company of Debride Inc., (“Debride”), which was incorporated under the laws of Florida on October 1, 2012 but did not commence operations until February 1, 2013. SpineZ Corp. changed its name to MedoveX Corp. and effected a 2-for-1 reverse split of its stock in March 2014.

The Company is in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company received CE marking in June 2017 for the DenerveX System and it is now commercially available throughout the European Union and several other countries that accept CE marking. The Company's first sale of the DenerveX System occurred in July 2017. The Company still intends to seek approval for the DenerveX System from the Food & Drug Administration (“FDA”) in the United States.

In October 2018, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), and subsequently amended in January 2019 (the “APA Amendment”) with Regenerative Medicine Solutions, LLC (“RMS”), Lung Institute LLC, RMS Lung Institute Management LLC, Cognitive Health Institute Tampa, LLC, RMS Shareholder, LLC and RMS Acquisition Corp. Pursuant to the terms of the Asset Purchase Agreement, the Company purchased all of the assets of RMS, Cognitive Health Institute Tampa, LLC, Lung Institute LLC and RMS Lung Institute Management LLC. The Company executed the Asset Purchase Agreement on January 8, 2019.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Solis Tek (SLTK) 43,541 26% -5.0 -491% 1,802 7,207 2,271 582 -8,858 -8,719 43,301
CCUR (CCUR) 43,359 0% 18.3 3% 62,474 10,118 3,290 0 1,771 2,014 36,876
Cleanspark (CLSK) 43,300 21% -1.1 -159% 32,912 2,881 2,321 481 -52,487 -43,644 47,784
Smartag International (SMRN) 42,619 100% -97.1 -501% 87 31 1 1 -438 -438 42,532
Mastermind (MMND) 42,338 88% 57.6 24% 2,419 256 5,286 4,643 576 727 41,906
Where Food Comes From (WFCF) 42,054 42% 16.2 4% 18,765 6,593 18,587 7,755 806 2,438 39,482
Union Bridge Holdings (UGHL) 41,808 20% -172.1 -308% 79 681 71 14 -243 -243 41,761
NaturalShrimp (SHMP) 41,113 -6.6 -209% 3,017 5,080 0 0 -6,312 -6,065 40,295
RXI Pharmaceuticals (RXII) 40,899 0% -4.1 -61% 12,108 2,401 78 0 -7,374 -7,298 30,033
Portsmouth Square (PRSI) 40,747 26% 1.5 5% 62,554 136,872 59,881 15,415 2,847 13,609 19,931
Medovex (MDVX) 40,543 70% -3.6 -69% 16,726 4,772 4,178 2,930 -11,561 -11,141 40,243
ATI Nationwide Holding (ATIN) 40,178 -649.2 -30,945% 0 6 0 0 -62 -62 40,178
Earth Science Tech (ETST) 39,246 53% -19.3 -600% 352 833 597 316 -2,113 -2,030 39,211
Cipherloc (CLOK) 38,753 85% -5.5 -43% 11,652 186 87 74 -5,012 -5,029 27,662
First Choice Healthcare Solutions (FCHS) 38,514 16.2 3% 27,801 7,984 0 0 832 1,917 31,130
Echelon (ELON) 38,425 55% -8.2 -17% 28,010 6,437 31,601 17,474 -4,655 -4,090 33,505
Protagenic (PTIX) 38,275 -17.0 -640% 350 729 0 0 -2,237 -2,237 37,936
Williams Industrial Services Group (WLMS) 37,976 14% -6.6 -11% 103,066 81,820 219,940 31,418 -11,645 -10,787 71,308
Pharmacyte Biotech (PMCB) 37,745 -11.8 -57% 5,606 607 0 0 -3,171 -3,170 37,417
Invesco DB US Dollar Index Bearish Fund (UDN) 37,692 -48.5 -2% 41,690 4,002 0 0 -780 -778 37,692

Balance Sheet ($'000)2015-12-312016-03-312016-12-312017-12-312018-12-31
Cash1,57047189324547
Accounts Receivable330157146
Inventory22295131
PP&E2526988730
Assets11,53210,2451,5081,228404
Accounts Payable278211226196751
Long-Term Debt165150104390
Liabilities1,5096891,9565152,401
Stockholders' Equity10,0239,556-448713-1,997
Income Statement ($'000)2015-12-312016-03-312016-12-312017-12-312018-12-31
Revenue33207818
Cost of Revenue25163503
Gross Profit845315
R&D9401,127491205
SG&A5,1035,2645,5874,781
Tax0
Net Income-6,523-16,227-6,456-4,909
Cash Flow ($'000)2015-12-312016-03-312016-12-312017-12-312018-12-31
Cash Operating-5,982-5,427-5,590-2,341
Cash Investing-1,159415-17150
Cash Financing2,0274,3354,9591,993